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Growing evidences indicate that proteases are implicated in adipogenesis and in the onset of obesity. We previously reported
that the cysteine protease cathepsin K (ctsk) is overexpressed in the white adipose tissue (WAT) of obese individuals. We herein
characterized the WAT and the metabolic phenotype of ctsk deficient animals (ctsk2/2). When the growth rate of ctsk2/2
was compared to that of the wild type animals (WT), we could establish a time window (5–8 weeks of age) within which ctsk2/
2display significantly lower body weight and WAT size as compared to WT. Such a difference was not observable in older mice.
Upon treatment with high fat diet (HFD) for 12 weeks ctsk2/2 gained significantly less weight than WT and showed reduced
brown adipose tissue, liver mass and a lower percentage of body fat. Plasma triglycerides, cholesterol and leptin were
significantly lower in HFD-fed-ctsk2/2 as compared to HFD-fed WT animals. Adipocyte lipolysis rates were increased in both
young and HFD-fed-ctsk2/2, as compared to WT. Carnitine palmitoyl transferase-1 activity, was higher in mitochondria
isolated from the WAT of HFD treated ctsk2/2 as compared to WT. Together, these data indicate that ctsk ablation in mice
results in reduced body fat content under conditions requiring a rapid accumulation of fat stores. This observation could be
partly explained by an increased release and/or utilization of FFA and by an augmented ratio of lipolysis/lipogenesis.
These results also demonstrate that under a HFD, ctsk deficiency confers a partial resistance to the development of
dyslipidemia.
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INTRODUCTION
Cathepsin K (ctsk) is a member of the papain-like cysteine protease
family. Members of this family are generally lysosomal enzymes
although some, including ctsk are also found secreted from the cell.
Ctsk has potent proteolytic activities against several extracellular
matrix components such as collagen I and II, elastase, osteonectin
and osteopontin [1–3]. Ctsk is most highly expressed in osteoclasts
and its major recognized function is in the process of bone
remodelling. However, broader potential roles for ctsk have been
revealed by the identification of ctsk in a number of other cell and
tissue types, including activated macrophages[4], thyroid [5],
lung[6], atheroma [7,8], and skin [9]. Ctsk mRNA and protein
were localized in samples of primary breast carcinoma [10] and
prostate cancer [11]and it was suggested that this protease, like
metalloproteases, may contribute to the invasive potential of
certain cancer cells through the digestion of the extracellular
matrix.
Several recent reports link cysteine cathepsins with metabolic
function. Taleb et al. [12] found that cathepsin S (ctss) gene
expression is augmented in adipose tissue of obese humans and
defined it as a novel marker of adiposity. Given the involvement of
this enzyme in the development of atherosclerotic lesions Rodgers
et al. [13], propose that ctss is a molecular link between obesity
and atherosclerosis. Inactivation of cathepsin B (ctsb) protects
against diet-induced fatty liver disease, as ctsb2/2 mice placed on
a high carbohydrate diet developed marked obesity, but not the
severe hepatomegaly, steatosis and associated dysmetabolic
syndrome observed in the wild type (WT) controls placed on the
same diet [14].
An even larger body of results indicate that metalloproteases
(MMP) also play an important role in obesity and that their activities
are important for the early events leading to adipogenesis. Chavey et
al. [15] found that MMP-2, MMP-3,MMP-12, MMP-14,MMP-19,
and TIMP-1, the endogenous MMP inhibitor, are strongly induced
in obese adipose tissues compared with lean tissues. In addition, they
and others found that pharmacological inhibition of MMP-2 and
MMP-9 decreased adipose conversion in vivo [16] and in vitro [17,18].
We have recently reported that ctsk is relatively highly expressed in
the white adipose tissue (WAT) and that it is a marker of adiposity as
its transcript is induced in murine and human obesity [19]. In
addition, we found that ctsk is a novel marker of adipogenesis, since
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its expression is progressively induced as 3T3-L1 preadipocytes
progress to adipose conversion. This may partly account for the
increase of ctsk observed in obesity in which de novo differentiation
takes place. We also demonstrated that the microphthalmia
transcription factors (mitf and TFE3), which are known to induce
ctsk expression in osteoclasts, are induced in the WAT of obese
animals. Interestingly, these transcription factors are activated by
macrophage colony stimulating factor (MCSF), which is also induced
in the adipose tissue of obese animals [20]. Furthermore, MCSF is
able to induce the expression of ctsk in some cell types such as
monocytic osteoclast precursors [21]. Ctsk induction therefore
appears as a mechanism where different pathways converge, raising
the question of the specific role and biological significance this
protease may play in adipose tissue and in obesity.
To address this issue, we have employed a loss of function
approach and have characterized ctsk null mice from a metabolic
perspective. These mice, first described by Saftig [22] and Lazner
[23] show impaired resorption of bone matrix and develop
osteopetrosis. However, no specific analysis of their metabolism or
energy homeostasis had been carried out so far. The results of the
present in vivo study indicate that ctsk ablation in mice results in an
altered body fat content in the young animals and a lowered
susceptibility to gain weight on a high fat diet in adult animals.
These data, therefore, provides new experimental evidence for the
involvement of ctsk in the regulation of fat storage and utilization.
RESULTS
Young ctsk2/2 mice show reduced fat mass
In previous descriptions of the ctsk null mice (ctsk2/2) [22–24]
no body weight differences compared to WT mice were
presented. Consistent with these findings, we did not observe
any significant body weight differences in adult (3 month old and
greater) male and female C57Bl6 ctsk2/2 mice as compared with
C57Bl6 WT animals, when fed a normal chow diet. Dissection of
fat pads (adult male epididymal and perirenal and adult female
gonadal) showed a moderate (12%), but not significant, reduction
in weight for male ctsk2/2, as compared to WT animals. No
significant differences between ctsk2/2 mice and controls were
found for the weights of liver or brown adipose tissue (BAT), or for
body length.
However, we noticed that at a younger age, C57Bl6 ctsk2/2
mice appeared to have a lower body weight, but similar body
length to C57Bl6 WT animals. We therefore measured the growth
rate of the animals starting from postnatal day (P) 10 to P120:
curves for males and females are respectively shown in Figure 1A
and 1B. 2-way analysis of variance (ANOVA) revealed a significant
(P,0.01) overall effect of genotype on the body weight during the
time window analyzed (F= 9.81, df = 1, F= 8.15 for males and
females respectively). A significant interaction between time and
genotype was observed for females (F = 2.13, df = 7, time X
genotype, P,0.05), but not for males. When Bonferroni post-tests
are performed, no significant differences were detectable during
the first 2 weeks of life for both genders, whereas at day 21 for
females and day 32 for males, ctsk2/2 mice show a significantly
lower body weight as compared to WT controls. Such a reduction
was observed until 8–9 weeks of age, after which no significant
differences between the 2 genotypes was observed (see legend of
figure 1 for statistical details).
We then investigated the reason for this reduced body weight in
the young, by assessing fat mass in 5–8 week-old mice. At this age,
the WAT is small, but well defined and dissectible. The weight of
Figure 1. Young C57Bl6 ctsk2/2 mice display reduced body weight. Growth curves from 10 to 120 days for male (A) and female (B) mice (n = 12
for males and n= 9 for females for each genotype. Statistical details for Bonferroni post-tests: males df = 22, t = 2.15 for day 32, t = 3.54 for day 42,
t = 2.08 for day 56; females df = 16, t = 2.63 for day 21, t = 2.81 for day 32, t = 2.14 for day 39, t = 3.22 for day 56. * P,0.05 . (C) Scattergram showing the
positive and significant correlation (Spearman regression analysis) (P,0.05) between MRI data, expressed as (fat volume)/(total body volume), and
the ratio fat pad/body weight of 10 animals.
doi:10.1371/journal.pone.0000683.g001
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the perigonadal fat pad, the most developed fat depot at this age,
was significantly decreased in male and female ctsk2/2 animals,
compared to WT mice (8667 mg versus 12769 mg, t = 3.68,
df = 58 P,0.001; 3565 mg versus 5665 mg, t = 2.77, df = 19,
P,0.02 for males and females respectively). No significant
differences were found in the weights of liver or BAT. In a group
of young C57Bl6 ctsk2/2 and ctsk +/+ female mice, adiposity
was also assessed non-invasively by magnetic resonance imaging
(MRI), that showed a significant reduction (more than 20%) of
body fat content in the ctsk2/2 mice (t = 2.38, df = 7, P,0.05).
Spearman linear regression analysis applied to adiposity (assessed
by MRI and expressed as (fat volume)/ (total body volume) against
fat pad/body weight in individual animals showed a significant
and positive correlation (R= 0.63, df = 9, P,0.05, figure 1C).
Based on this result we used the weight of one or more fat pads (if
dissectible) as an indicator of adiposity when MRI was not
available.
Differences in food intake could account for the reduction in fat
depots in young ctsk2/2 mice. When this parameter was
evaluated, no significant differences in the weight of chow food
per mouse per day were found between ctsk2/2 and WT mice
for young (3.8361.13 versus 3.9561.36 g/ mouse/day) or adult
animals (4.0461.35 versus 3.9761.57 g/ mouse/day).
Plasma biochemistry of ctsk2/2 mice
Since age appeared to determine the extent of differences between
C57Bl6 ctsk2/2 and WT animals, metabolic parameters
(Table 1) were measured using 5–8 week old male (defined as
young) and 12–20 week old male mice (defined as adult). 2-way
ANOVA was applied to the data reported in table 1. Using this
test no significant interaction between genotype and age was
assessed for any of the variables under study. When a significant
overall effect of genotype was detected a Bonferroni post-test was
applied for the pairwise comparison (e.g. young wt versus young
KO) and the relative significance is reported in table 1. Non-
fasting plasma glucose levels, as well as free fatty acids levels were
not significantly altered by the absence of ctsk in young and adult
male ctsk2/2 mice. However when circulating FFA were
measured in a small group of young animals (n = 4) after an
overnight fast, we found significantly higher values in ctsk2/2
mice as compared to WT controls (845.1623.2 mEq/l versus
582.6621.5 mEq/l, t = 7.7, df = 6, P, 0.001). 2-way ANOVA
indicates a significant (P,0.05) overall effect of genotype on non-
fasting plasma triglyceride levels, with both young and adult
ctsk2/2 mice showing moderately and not significantly reduced
levels. An overall significant reduction (F= 12.11, df = 1 P,0.01)
of non-fasting insulin due to ctsk deficiency was also evidenced by
2-way ANOVA and Bonferroni post-test revealed significantly
lower levels in adult ctsk2/2 mice (t = 3.03, df = 15, P,0.05). An
intraperitoneal glucose tolerance test (IpGTT) performed in adult
male animals showed that in ctsk2/2 mice, postloading plasma
glucose levels, as evaluated by the incremental area over basal
values during 120 min (DG), were significantly (t = 4.59, df = 14,
P,0.01) lower than in WT controls (DG=553.74673.54 and
1145.786111.82 mg/l/min in ctsk2/2 and WT mice, respec-
tively). The glucose stimulated rise in circulating insulin was
substantially similar in the two groups. These results indicate that
glucose tolerance is improved and insulin sensitivity is well
preserved in ctsk-deficient animals. 2-way ANOVA indicates that
ctsk deficiency results in a significant overall reduction of plasma
leptin (F= 9.08, df = 1, P,0.01). A trend toward reduction of
plasma leptin was observed in young male ctsk2/2 mice (table 1),
and plasma leptin levels were significantly lower in adult male
ctsk2/2 mice (table 1), as compared with relative controls
(t = 3.02, df = 14, P,0.05). Since circulating leptin is a sensitive
marker of adiposity, this decrease is consistent with the observed
reduction of the fat mass in young ctsk2/2 animals and suggests
a latent alteration in adiposity in the adult animals. Together these
data suggest that the metabolic profile of ctsk2/2 mice is
somewhat altered in adult animals, where an apparent decrease of
adiposity is not observable.
Ctsk2/2mice are partially resistant to high-fat diet-
induced obesity
Since an altered metabolic phenotype in ctsk2/2 mice on
a regular diet was clearly observed only in young animals, we
challenged adult mice with a high fat diet (HFD) containing 35%
fat and 35% carbohydrate (by weight) for 12 (sv129Bl6) or 13
(C57Bl6) weeks to stimulate weight gain. This experiment was
performed in the colony of C57Bl6 (ctsk2/2 and +/+) mice
where the characterization of the adult and young mice so far
described had been performed, and in an independent colony bred
on the mixed genetic background sv129/C57Bl6 (males and
females ctsk2/2 and +/+). Results were qualitatively overlapping
and the data sets for both groups are summarized in table 2. Due
to the important effect exerted by strain on the different variables,
data were analyzed only within the separate groups (e.g C57 Bl6
male ctsk2/2 versus WT). In the case of sv129/Bl6 mice, males
and females were investigated in independent experiments,
making any statistical comparison unlikely. For all groups, the
intake of the HFD was not significantly different (assessed by 2-
way ANOVA) in WT and in ctsk2/2 animals. The representative
graph shown in figure 2A is relative to weekly measurements of
food intake in HFD treated C57Bl6 male mice: the average
consumption calculated for these animals is 2.7960.05 g/mouse/
day for WT and 2.6960.04 g/mouse for ctsk2/2 mice). Sv129/
C57Bl6 animals (males and females) were started on the HFD at
Table 1. Metabolic parameters of young and adult C57Bl6 ctsk +/+ and ctsk2/2 male mice.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Young wt Young ctsk2/2 Adult wt Adult ctsk2/2
Non fasting glucose (mM) 7.7060.59 (n = 9) 7.7060.86 (n = 7) 8.9160.33 (n = 16) 9.4360.30 (n = 14)
Non fasting FFA (mEq/l) 620.9685.3 (n = 9) 515.96114.2 (n = 8) 326.9619.1 (n = 12) 383.1622.2 (n = 9)
Non fasting triglycerides (mM) 1.2660.15 (n = 9) 1.0260.16 (n = 6) 1.160.07 (n = 16) 0.960.05 (n = 14)
Non fasting insulin (ng/ml) 0.960.11 (n = 8) 0.6560.12 (n = 5) 0.6560.06 (n = 9) 0.2960.018 (n = 8) **
Non fasting leptin (ng/ml) 3.5860.31 (n = 10) 3.0660.18 (n = 8) 5.8960.34(n = 8) 4.5360.36 (n = 8) *
Bonferroni post-test
*P,0.05
**P,0.001
doi:10.1371/journal.pone.0000683.t001..
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8–9 weeks of age. At this age, female ctsk2/2 exhibited a slightly
lower body weight than WT animals. 2-way ANOVA applied to
data shown in Figure 2B (top panel) indicate a significant
interaction between genotype and time (F= 1.86, df = 11, time
X genotype, P,0.05) and a significant (F= 28.03, df = 1,
P,0.0001) genotype effect on weight gain, with ctsk2/2 female
mice showing lower weight gain that WT. Statistical significance
for post-tests performed on pairwise comparisons was observable
starting from the 9th week of diet (week 9, t = 2.29, P,0.05; week
10, t = 3.3, P,0.05; week 11, t = 4.14 P,0.001; week 12, t = 3.60
P,0.01. Df = 18 in all weeks).
2-way ANOVA applied to data reported in table 2 indicate an
overall significant effect of genotype on sv129/C57Bl6 male and
female body weight (F = 5.03, df = 1, P,0.05, F= 15.26, df = 1,
P,0.001 for males and females respectively): Bonferroni post-tests
revealed a significant difference at the end of the treatment in
females (week 12) (t = 4.7, df = 18 , P,0.001), but not in males.
Indeed ctsk2/2 females gained only 51% of the weight gained by
WT animals (Figure 2 B, top panel). This result was reflected by
the fat content of these animals, as assessed by DEXA, at the end
of the study, which was 66% that of WT (2-way ANOVA,
F= 8.47, df = 1, P,0.01, post test at week 12, t = 3.41, df = 18,
P,0.01). Bone mineral density (BMD, Table 2) was also assessed
by DEXA and showed an overall significant increase in ctsk2/2
animals as compared with WT both in males and in females (2-
way ANOVA, F=11.32, df = 1, P,0.005, F= 75.23, df = 1 ,
P,0.0001 for males and females respectively). This is expected
given the severely impaired bone resorption determined by ctsk
deficiency, which results in the unusually dense trabeculation of
the bone marrow spaces, characterizing the osteopetrotic pheno-
type of these mice [22]. This mechanism seems to completely
overcome the increased bone resorption that would result from the
relatively low leptin levels [25,26] observed in the ctsk2/2
animals (both on the chow and on the high fat diet) as compared to
those of the WT.
A significant resistance to weight gain could be demonstrated in
male C57Bl6 ctsk2/2 animals (2-way ANOVA, F=27.4, df= 1,
P,0.001, Bonferroni post-test, week 13 of the diet, t = 5.30, df = 18,
P, 0.001, Table 2). These animals showed a lower (not significant)
body weight at 8 weeks of age, before the HFD was initiated, as
compared to wild type controls. This body weight difference became
larger as HFD treatment progressed, with C57Bl6 male ctsk2/2
mice exhibiting 72% of the final weight gain and 76% of the adipose
mass of WT controls (as assessed by MRI) after 13 weeks (Table 2 ,
MRI data are expressed as 100 x (fat volume/total body volume and
Figure 2B, bottom panel). 2-way ANOVA applied to data shown in
Figure 2B (bottom panel) indicate a significant interaction between
genotype and time (F=3.05, df = 11, time X genotype, P,0.001)
and a significant (F=11.27, df= 1, P,0.001) genotype effect on
weight gain, with ctsk2/2 male mice showing lower weight gain
that WT. Statistical significance for post-tests performed on pairwise
comparisons was observable starting from the 11th week of diet,
(week 11, t = 2.26, P,0.05; week 12, t = 3.90, P,0.01; week 13,
t = 3.95, P,0.01. Df=18 in all weeks)
Consistent with the above results, when individual fat depots
were dissected at the end of the treatment, C57Bl6 male ctsk2/2
mice displayed a significant reduction of epidydimal WAT
(t = 3.75, df = 16, P,0.01) perirenal WAT ( t = 2.82, df = 16,
P,0.05) and BAT (t = 2.16, df = 15, P,0.05) as compared to WT
animals (Figure 2C). Accordingly, histological analysis revealed
that adipocyte size was reduced in the ctsk deficient animals
(Figure 2D). In addition, at the end of the diet, liver weights were
also significantly smaller in C57Bl6 ctsk2/2 male mice as
compared to WT (1442664 and 1777687 mg for ctsk2/2 and
+/+ mice respectively, t = 2.45, df = 16 P,0.01). Hepatic tri-
glyceride content was lower in ctsk2/2 as compared with WT
mice (124634 versus 153624 mg/g of liver, n = 3), although this
difference did not reach statistical significance.
Various metabolic parameters were also assessed at the end of
the 12/13-week HFD in C57Bl6 and sv129/C57Bl6 (Table 2).
Table 2. Effects of HFD on metabolism and weight in ctsk +/+ and ctsk2/2 mice.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Week Sv129/C57Bl6 females Sv129/C57Bl6 males C57Bl6 males
+/+ 2/2 +/+ 2/2 +/+ 2/2
Body Weight (g) 0 19.560.4 AAA 18.160.2 28.360.4 A 26.960.7 25.760.5 AAA 22.460.4
12/13 32.961.9 24.961.4*** 43.261.6 39.861.1 47.861.4 39.161.4***
Body Fat (%) 0 13.460.7 # AA 11.160.5 # 13.160.6 # 14.160.9 # - -
12/13 33.763.8 # 22.162.8 # ** 32.862.7# 32.561.0 # 55.661.4 1 44.962.1***/1
BMD (mg/cm2) 0 47.160.4#AAA 51.860.5 # *** 50.960.6 AA 51.961.3 - -
12/13 53.460.7 # 60.561.0 # *** 54.160.6 58.660.8*** - -
Non fasting Blood
Glucose (mM)
0 7.260.2 7.660.2 7.860.3 8.060.4 9.360.5 9.660.4
12/13 6.860.7 6.160.2 7.460.5 6.460.3 11.760.3 11.461.0
Triglycerides (mM) 12/13 1.6460.17 1.5960.08 1.7660.11 1.4260.07* 0.9760.035 0.7960.03**
Cholesterols (mM) 12/13 3.7360.27 3.1460.12 P = 0.054 5.1960.24 3.6560.27** 3.7560.18 2.4160.19***
Insulin (ng/ml) 12/13 1.2260.19 0.6160.09 P = 0.057 5.9661.1 3.4560.6 * 1.4560.31 1.8560.27
Leptin (ng/ml) 12/13 32.2468.73 11.7964.2* 83.75614.45 37.2465.3 * 52.1263.84 28.367.49*
In the ‘‘week’’ column, 12 is referred to sv129Bl6 mice and 13 is referred to C57Bl6 mice.
*p,0.05,
**p,0.01 and
***p,0.001 compared to the +/+ mice of same sex, same week and same strain (t-test or Bonferroni post-test)
A p,0.05, AA p,0.01, AAA p,0.001 2-way ANOVA.
#Assessed by DEXA,
1Assessed by MRI
doi:10.1371/journal.pone.0000683.t002..
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Non-fasting blood glucose levels were not different among the
different genotypes in any of the groups, while insulin levels were
reduced in sv129/C57Bl6 ctsk2/2 females (t = 2.80, df = 18,
P,0.05) and males (t = 2.03, df = 22, P= 0.057). Triglycerides
were significantly decreased in ctsk2/2 male mice of both
colonies (t = 2.6, df = 20, P, 0.05, t = 3.97, df = 16, P, 0.01 for
sv129/Bl6 and C57Bl6 respectively), but not in sv129/C57Bl6
females, whereas cholesterol was decreased in all groups analyzed
(t = 2.06, df = 18, P= 0.05; t = 4.15, df = 22, P,0.05; t = 5.07,
df = 16, P,0.001 for respectively sv129/Bl6 females and males
and for C57Bl6 males) At the end of the treatment leptin was
significantly reduced in all groups of ctsk2/2 mice as compared
to relative controls (t = 2.11, df = 18, P,0.05; t = 2.80, df = 20,
P,0.05; t = 2.91, df = 16, P,0.05 for respectively sv129/Bl6
females and males and for C57Bl6 males).
The same metabolic parameters were also measured in male
and female sv129/C57Bl6 ctsk2/2 and WT mice fed a regular
chow diet over a period of 12 weeks starting at 8–9 weeks of age.
Figure 2. WT and ctsk2/2 mice belonging to 2 independent colonies of mice (respectively bred on the mixed sv129/C57Bl6 and pure C57Bl6
genetic background) were fed a high-fat diet (HFD) starting at 8–9 weeks of age. (A) Representative graph showing food intake in C57Bl6 male
mice (n = 10). Food intake was monitored weekly in the two groups studied (see text for further explanations) and no significant differences between
genotypes were observed. (B) Graphs showing the increase in body weight with time for the sv129/C57Bl6 females and for the C57Bl6 males (n = 10
for both groups). The increases in body weight were calculated based on the initial body weight at day 0 of HFD feeding. (C) Weights of epididymal
WAT, perirenal WAT and BAT, taken from 5 month C67Bl6 old male mice (n = 9 for ctsk2/2 and for WT) after 12 weeks of HFD. Results are mean 6
SEM * p,0.05, ** p,0.01, ***p,0.001. (D) Representative histological sections of epididymal WAT from C57Bl6 ctsk+/+ (left panel) and ctsk2/2
(right panel) mice maintained on a high fat diet for 12 weeks.
doi:10.1371/journal.pone.0000683.g002
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Apart from the higher BMD of ctsk2/2 animals, no significant
differences in body weight were observed for mice with ctsk
deficiency compared to WT animals (data not shown).
As noted above, food intake was similar in the two genotypes on
either a normal chow or HFD. Moreover, the stool fat content of
a further colony of sv129/C57Bl6 female WT and ctsk2/2 mice,
which were fed a HFD for 12 weeks and which showed
a significant difference in weight gain, was not significantly
different (data not shown). This result rules out the possibility that
the observed differences in fat accumulation and circulating
triglycerides were due to differential intestinal absorption or
excretion.
The question then rises whether the output of energy was
different in the HFD-fed ctsk2/2 mice as compared to HFD-fed
controls. Since in vivo parameters like O2 consumption and body
temperature were not measured during the HFD experiment we
wanted to retrospectively determine if BAT was differently
activated in the two groups of animals. Western blot analysis
performed with an antibody directed against mouse uncoupling
protein 1, a reliable indicator of BAT activation [27], did not show
significant differences between the two genotypes, although an 8%
increase was detected in the BAT of C57Bl6 HFD ctsk2/2 mice
with respect to HFD WT (supplementary data. Figure S1 A and
B).
Taken together, the above results suggest that ctsk deficiency
confers a partial resistance to the development of morbid obesity
on a HFD and that ctsk deficiency protects mice from the onset of
dyslipidemia. The effect of the HFD was confined to homozygous
ctsk deficient animals as no weight gain, or metabolic effects, were
observed with heterozygous animals (data not shown).
WAT gene expression in young and HFD fed ctsk2/2
mice
To examine the molecular basis for the altered adipose mass and
lipid profile in the C57Bl6 young and HFD fed male ctsk2/2
mice, we measured by real time PCR the expression of genes
marking adipocyte terminal differentiation and/or involved in
fatty acid metabolism. In young mice, where the adipose tissue is
very small and more enriched in undifferentiated cells and stromal
vascular fraction (compared to adult animals), we isolated the
adipocyte fraction (AF) and pooled samples from 20 animals. In
these young mice, gene expression of adipocyte fatty acid-binding
protein (aP2), which regulates systemic glucose and lipid
metabolism [28], was reduced by 43% in the AF of the ctsk2/
2 mice as compared to WT animals. At variance, leptin gene
expression was not affected. Conversely, in adult ctsk2/2 (n = 4)
fed a HFD for 12 weeks, we observed a higher expression of aP2
gene (50%) and a lower content of leptin mRNA (236%) as
compared to WT mice. The latter observation is consistent with
the lower adipose mass and serum levels of leptin described in
HFD fed C57Bl6 ctsk2/2 mice (Table 2).
Genes involved in fatty acid metabolism and storage present
a consistent picture, in that glycerol phosphate acyltransferase
(GPAT), diacyglycerol acetyl transferase (DGAT) and fatty acid
synthase (FAS) were all increased in the AF of young ctsk2/2
mice (19%, 90% and 45% for GPAT, DGAT and FAS
respectively), as well as in adult male ctsk2/2 mice fed a HFD
for 12 weeks (29%, 18% and 296% for GPAT, DGAT and FAS
respectively) compared to WT controls. These data suggest that
a pattern of gene activation for lipid synthesis and storage occurs
in the WAT of ctsk2/2mice. This is surprising given the reduced
fat mass of both young and HFD-fed ctsk2/2 mice as compared
to controls.
CPT activity and lipolysis
Since the above gene expression data point toward a greater
storage capacity of ctsk2/2 WAT, the leaner phenotype of null
mice could be explained if fat cells could also display an enhanced
free fatty acid (FFA) oxidation rate. To test this hypothesis, we
assessed carnitine palmitoyl transferase-1 (CPT1) activity in
isolated mitochondria of ctsk2/2 young and HFD-treated
(12 weeks) male mice. CPT1 activity was significantly increased
(32%, t = 2.89, df = 5, P,0.05) in the WAT of C57Bl6 HFD
ctsk2/2 mice as compared to WT controls (Figure 3A), whereas
there was no difference between young WT and ctsk2/2 mice
(not shown). This implies a greater mitochondrial delivery of FFA
for beta-oxidation in HFD fed ctsk2/2 mice and suggests that
beta-oxidation exceeds lipid synthesis, thus resulting in a leaner
phenotype of HFD-fed ctsk2/2 mice as compared to HFD-fed
WT animals.
An alternative physiological mechanism leading to a lower
adipocyte lipid content could result from differences in FFA release
from intracellular stores. Lipolysis was therefore evaluated both
under basal conditions and following stimulation with the b3
agonist and lipolytic agent isoproterenol, in adipocytes isolated
from young and HFD-treated male C57Bl6 ctsk2/2 mice and
compared to that of C57Bl6 controls. ANOVA revealed an overall
significant genotype effect on lipolysis activity in young (F = 15.6,
df = 1, P,0.005) but not in HFD treated animals. Adipocytes from
young ctsk2/2 mice displayed a significantly increased lipolytic
activity (as assessed by Bonferroni post-tests), both in standard
assay conditions (3.5-fold, t = 3.15, df = 6 P,0.05) and upon
isoproterenol stimulation (3-fold, t = 2.74 , df = 6, P,0.05)
(Figure 3B, top panel). Adipocytes from HFD ctsk2/2 mice
showed a moderate induction (33%) of lipolysis after isoproterenol
treatment, although this increase was not statistically significant
compared to WT animals (Figure 3B, bottom panel). These data
demonstrate that in ctsk deficient animals the impaired capacity
for fat storage in adipocytes could be due to a high lipolytic rate in
the young and to an increased rate of FFA oxidation in the HFD
fed mice. These two mechanisms acting separately, or in
combination, could outweigh the effects of the increases in
expression of enzymes involved in lipid biosynthesis.
Adipogenesis in ctsk2/2 mouse embryo fibroblasts
As shown above, in HFD treated ctsk2/2 mice fat depots and
adipocyte size are smaller as compared with HFD treated WT.
These findings, together with the observation that young ctsk2/2
are delayed in the accumulation of fat stores, prompted us to
analyze adipocyte differentiation in the absence of ctsk. Mouse
embryonic fibroblasts isolated from C57Bl6 ctsk2/2 and WT
embryos were induced to differentiate, as described in ‘‘Methods’’.
Phase-contrast observations performed on these cells at various
time points allowed us to establish that adipogenesis was reduced
in cells derived from ctsk2/2 mice, as indicated by oil red ‘o
staining (Figure 4A). Furthermore, the expression of specific
adipocyte markers such as aP2, leptin and lipoprotein lipase was
diminished by .60% in ctsk2/2 embryonic fibroblasts (t = 9.15,
df = 5, P,0.001, t = 2.96, df = 5, P,0.05, t = 4.26, df = 5, P,0.01
for aP2, leptin and LPL respectively) (Figure 4B).
DISCUSSION
Data presented in this study further strengthen the concept that
ctsk is involved in energy balance and more specifically in the
homeostasis of adipose mass. Young ctsk2/2 mice showed
reduced fat mass, as compared to age-matched WT controls.
Adult ctsk2/2 mice, which do not display overt phenotypic
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alterations when fed a normal diet, displayed a partial resistance to
weight gain and to development of dyslipidemia when challenged
with a HFD. The lower body weight was reflected in a diminished
fat mass and, consistently, in lower serum leptin concentrations.
Variability in weight gain among various colonies of wild-type or
ctsk2/2 mice may depend on differences in genetic background.
Adipose tissue is an organ with significant plasticity since it is
able to undergo rapid dynamic changes. These changes take place
during the rapid enlargement of adipose mass in mice soon after
weaning and upon metabolic challenge represented, for instance,
by the HFD, which forces the animal to store an abnormal excess
of energy. In rodents, body fat content at birth is low and WAT is
barely detectable [29]. Two major morphologic changes take
place and contribute to the development and enlargement of the
fat depot in mice. Until the age of 40 days (P40) an intense period
of cell adipocyte hyperplasia is observed, whereas the period
between P40 and P80 is characterized by hypertrophy. Maximal
lipogenic activity, by which adipocytes are filled with triglycerides,
peaks at P40 [29]. Interestingly, the most prominent effect on fat
mass that we have noticed in ctsk2/2 male animals falls between
P32 and P56, suggesting that lipogenesis and cell hypertrophy are
affected by ctsk deficiency. In females this effect appears earlier, at
P21. Further, data obtained on mouse embryonic fibroblasts
indicate that ctsk deficiency results in a reduced capacity to
undergo adipogenesis, and this further strengthens the concept
that this protease is likely involved in the development of adipose
tissue, in line with what reported by Xiao et al. [30].
Two different, but not necessarily alternative hypotheses can be
formulated to explain the involvement of ctsk in adipogenesis and
in situations requiring increased adipose tissue plasticity, such as
the postnatal period or feeding with HFD. The first derives from
the high capacity of ctsk to digest important components of the
extracellular matrix, such as type I collagen and elastin. Because of
this activity, ctsk has been implicated in diseases involving bone
and cartilage destruction [31–33]. Ctsk has also been detected in
breast and prostate cancer where its role seems to be associated
with the invasive potential of these tumours, in addition to matrix
degradation [34,35]. Enlargement of the adipose mass, such as
that seen in the post-weaning period and upon HFD feeding,
involves massive remodelling caused by increased cell size and
number and by new vessel formation. Thus, the activity of ctsk
could facilitate this process to which other proteases also
participate. Therefore, in the long term and in a static situation
(such as in the adult mouse) an effect of ctsk deficiency may not be
observed since its function may be compensated by the
upregulation of other proteases. Metalloproteases (MMP-2 and
Figure 3. FFA utilization and release in ctsk +/+ and ctsk2/2 mice. (A) CPT activity of WAT mitochondria from HFD-fed C67Bl6 WT and ctsk2/2
mice. Results are the mean6 SEM for 4 WT and 3 male ctsk2/2mice (40 days-old) p,0.03 compared to WT mice. (B) Glycerol release was measured
in adipocytes isolated from the visceral adipose tissue of C57Bl6 WT and ctsk2/2 mice maintained in basal medium (ctr), or stimulated for 1 h with
1 mM isoproterenol (iso). Top and bottom panels show respectively the results obtained with young male animals (44 days-old) and with male
animals maintained on HFD for 12 weeks. Results are the mean 6 SEM for 4 independent experiments. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0000683.g003
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MMP 9) are present in WAT, where they play a role in
adipogenesis [15] and recent work by Taleb et al. [12] shows that
the cysteine protease cathepsin S is expressed in WAT where it
promotes adipogenesis potentially via the degradation of fibro-
nectin.
The second, more speculative, hypothesis figures a role for ctsk
not only in the environment surrounding the adipocyte, but also in
the activation of pathways affecting adipocyte physiology and
metabolism. It is difficult to explain such effects for a lysosomal
and secreted protein, known to act on the extracellular matrix.
Unfortunately, antibodies directed against ctsk which are reported
to work well in other tissues, give a very poor and often non-
specific signal in the WAT, and for this reason, our attempts to
better define the localization of ctsk within adipose tissue have so
far been unsuccessful. However, recent findings indicate that other
cathepsins can change their localization depending on cellular
conditions. For instance, cathepsin L (ctsl) isoforms devoid of the
signal peptide, can localize to the nucleus and process the
transcription factor CDP/Cux involved in the G1/S transition
[36]. Such isoforms are translated from ATGs located downstream
of the methionine codon 1. Although the amino acid sequences of
ctsk and ctsl present only 45% homology, the internal translation
start sites present in ctsl (Met 77 and Met 83) are perfectly
conserved in ctsk. Indeed, Goulet and coworkers report that ctsk is
capable of cleaving CDP/Cux, although to a lesser extent [36].
Based on these observations it is possible that ctsk is able to localize
in subcellular compartments other than the lysosome and
participate in the activation of metabolic pathways.
The reduced capacity of ctsk2/2 mice to accumulate fat mass
in spite of an equal caloric intake suggests that the absence of ctsk
is associated with increased energy expenditure, which might be
due to increased BAT activation. Yet, we could not demonstrate
a significant increase of UCP1 content in BAT from ctsk2/2
mice as compared with controls. This does not rule out an
involvement of BAT in increased thermogenesis of ctsk2/2 mice
but other, possibly additional, mechanisms acting in other tissues
should be considered. Indeed, we found that the reduced capacity
of ctsk2/2 mice to accumulate fat mass is not due to decreased
expression of lipogenic enzymes but to an increased turn-over of
free fatty acids. Indeed, on one hand our gene expression studies in
WAT point toward a pattern of induction in a number of genes
involved in fatty acid synthesis (increased FAS) and esterification
(moderately increased GPAT and DGAT), which should favour
and not hinder TG storage. On the other hand, a highly enhanced
rate of lipolysis and increased CPT-1 activity were detected in the
WAT of young and HFD-fed adult ctsk2/2 mice, respectively.
Such metabolic features suggest that adipocytes of ctsk2/2 mice
have an increased capacity to release and/or oxidize fatty acids,
which makes them less prone to TG storage during early post-
natal development or upon increased lipid availability, despite
enhanced expression of lipogenic enzymes. It is likely that in ctsk-
deficient animals, the turnover of FFA is accelerated because of
enhanced lipolysis and an increased rate of the futile TG-FFA
cycle (particularly in young mice), as well as an enhanced FFA
utilization for beta-oxidation (particularly in HFD-fed adult mice).
These changes ultimately result in the less efficient storage of
triglycerides. The increased rate of FFA recycling, which in fasting
rodents and humans accounts for 30–40% of WAT FFA disposal
[37], is reminiscent of a hyperthyroid phenotype, which however
can be ruled out based on the slight hypothyroidism of the ctsk2/
2 mice [5]. The similar, if not higher, degree of BAT activation
observed in HFD-fed ctsk2/2 mice, despite their lower body fat
content, suggests that energy expenditure is also probably slightly
increased in this model. An hypothetical model of how cathepsin k
deficiency impacts on accumulation of fat mass is represented in
figure 5.
Overall our data indicate that ctsk ablation in mice results in
a reduced body fat content under conditions requiring a fast
accumulation of fat stores, namely, the post weaning period and
the exposure to a high fat diet. This observation emphasizes the
similarity of these two conditions and indicates ctsk as a permissive
factor for WAT ‘‘plasticity’’, intended as capacity to rapidly
accumulate energy stores. This may have important implications
to understand the onset of obesity in the very young and the
relationship between childhood and adulthood obesity.
The reduced body fat content observed in ctsk2/2mice can be
partly explained by an increased release and/or utilization of free
fatty acids and potentially by an augmented ratio of lipolysis/
lipogenesis. Further, our results demonstrate that under a HFD,
ctsk deficiency confers a partial resistance to the development of
dyslipidemia. Unfortunately current human ctsk K inhibitors are
neither potent, nor selective against the rodent enzymes, therefore
precluding the testing of this hypothesis pharmacologically in mice
or rats. However, ctsk inhibitors are presently under evaluation in
clinical trials for the treatment of osteoporosis, osteoarthritis and
metastatic bone disease [38]. This will enable the metabolic effects
observed in mice to be more fully explored clinically in humans.
METHODS
Experimental animals
The strategy used to target the cathepsin K locus and generate ctsk
null mice was as previously described [22]. These animals were
originally generated on a C57Bl6 x sv129 background. Two
Figure 4. Ctsk deficiency interferes with adipogenesis. (A) Adipocyte
differentiation from mouse embryo fibroblasts of C57Bl6 wild type (WT)
and ctsk2/2 mice (KO). Mouse embryo fibroblasts were prepared
12 days post-coitum and were induced to differentiate in adipocytes. At
10 days after the addition of adipocyte differentiation media we
performed oil red O staining (10 X magnification). (B) Quantification of
aP2, leptin and LPL mRNA expression after real time PCR in WT (black
bars) and ctsk2/2 (white bars) MEF. Results are the mean 6 SEM for 4
independent experiments. Statistical details for aP2, leptin and LPL are
respectively: t = 9.15, t = 2.96 and t = 4.26, df = 5 in all cases. * p,0.05,
**p,0.01, ***p,0.001 versus WT.
doi:10.1371/journal.pone.0000683.g004
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colonies of mice were used in this study. Animals used both for the
characterization of the adult and young phenotype and in the high
fat diet experiment were backcrossed for 8 generations onto
a C57Bl6 background. An additional group of animals, used only in
the high fat diet experiment, were on the mixed sv129/C57Bl6
background. All studies comparing ctsk2/2 and WT mice used
littermate animals. We used the parental wild type inbred strain as
controls. Mice (0–12 months of age) were housed in a pathogen free
barrier facility (12-h light/12-h dark cycle). Mice were placed on
either a normal chow (2018 Teklad global diet, 18.9% protein,
5.7% fat and 57.3 % carbohydrate, Harlan Teklad) or on high fat
high carbohydrate diet for 12 weeks (Diet F3282, 19% protein, 35%
fat and 35 % carbohydrate, Bioserve Frenchtown, New Jersey).
During the HFD treatment, food intake and body weight were
measured weekly. Animals were killed by CO2 asphyxiation or
cervical dislocation. Gonadal and perirenal fat pads, brown adipose
tissue and liver were dissected, weighed and then promptly frozen in
liquid nitrogen for biochemical and molecular studies. Blood was
withdrawn from euthanized animals by cardiac puncture. All
animal protocols were approved by the local ethical committees.
The experimental protocols followed the Principles of Laboratory
Animal Care (US NH publication Nu 83–85, revised 1985).
Blood collection
Unless otherwise specified, metabolic parameters were assessed in
blood samples obtained from conscious non-fasting animals
between 10 and 11 a.m. Blood samples were taken from the tail
vein using EDTA coated tubes and centrifuged in a refrigerated
microfuge. Plasma was collected and stored at 220uC for
subsequent assays.
Intraperitoneal glucose tolerance test
Glucose (1.5 g/kg) was given as a 16.5% solution to conscious
non-fasting animals. Blood samples were collected sequentially
from the tail vein before and 15, 60, 120 and 210 min after
glucose injection.
Assays
Plasma glucose was measured by a glucometer (Precision QID,
MediSense) or by the glucose oxidase method using commercial
kits (Glu-cinet, Sclavo Diagnostics International, Siena, Italy).
Plasma insulin was measured by radioimmunoassay (RIA)
according to Herbert et al. [39], using insulin antibody and 125I-
labeled insulin from Linco (Linco Research, Inc., St. Charles,
MO, USA). FFA concentrations were determined by the Wako
NEFA C test (Wako Chemicals GmbH, Neuss, Germany). Plasma
TG and cholesterol levels were assayed using commercially
available kits (Vitros or Chema Diagnostica, Iesi, Italy). Plasma
leptin was measured by radioimmunoassay, using a Linco RIA
kit, specific for mouse leptin (Linco Research, Inc., St. Charles,
MO, USA). Alternatively mouse insulin and leptin were de-
termined simultaneously by electrochemiluminescence (Meso
Scale Discovery).
Isolation of total RNA and real time PCR
Total RNA was isolated from frozen tissues or from cells with
Tripure (Roche Molecular Biochemicals) and its integrity was
evaluated on a formaldehyde denaturing agarose gel. RNA was
treated with Rnase-free Dnase (Roche Molecular Biochemicals) to
remove any contaminating genomic DNA. First-strand cDNA
Figure 5. Hypothetical scheme representing how ctsk ablation in mice may result in partial resistance to increase adipose mass in conditions
requiring rapid accumulation of fat stores. In wt mice (intact genome, left side of the panel) ctsk participates to WAT extra-cellular matrix
remodelling, thus facilitating the enlargement of the adipose mass, which implies adipocyte size increase and de novo differentiation of pre-
adipocytes. Mechanisms involving an intracellular action of ctsk are also hypothesized. In ctsk deficient animals (right side of the panel) stimuli
directed to increase the adipose mass are partially blunted and the extra caloric intake is partly utilized in a futile cycle, consisting of increased
synthesis of triglycerides, increased triglycerides hydrolysis and increased b-oxidation of FFA.
doi:10.1371/journal.pone.0000683.g005
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synthesis was performed using oligo hexamers (Pharmacia) (see
[19] for detailed protocols).
Taq-Man quantitative PCR (50uC for 2 min, 95uC for 10 min,
followed by 40 cycles of 95uC for 15 s 60uc for for 1 min) to
amplify samples for aP2, glycerol phosphate acyltransferase
(GPAT), diacyglycerol acetyl transferase (DGAT), fatty acid
synthase (FAS), lipoprotein lipase (LPL) and leptin. The relative
abundance of mRNAs was calculated with Tata Binding Protein
mRNA as the invariant control. The primers used were all
purchased from Applied Biosystems.
Preparation of isolated adipocytes
Isolated fat cells were obtained with a modification to the method
of Rodbell [40]. Briefly, visceral adipose tissue was dissected,
rapidly washed in PBS, then minced and digested for 1 h with
shaking at 37uC with Collagenase A (20 mg/ml from Clostridium
histolyticum, SIGMA # 103578) in Krebs Ringer Bicarbonate
buffer (KRBH-buffer), containing 10mM NaHCO3,30 mMHepes
and 1% BSA(Sigma) at pH 7.4.
1 ml of collagenase solution was added to 4 g of fat pad in
KRBH-buffer. Fat cells were filtered through nylon mesh
(250 mm) and washed twice with the same incubation buffer.
After the final wash the adipocytes were suspended in Dulbecco ‘s
modified Eagle’s medium (DMEM) supplemented with 10% FCS
(Gibco), 200U/ml penicillin and 50 mg/ml streptomycin.
Measurement of lipolysis
Measurement of lipolytic activity was performed by incubating
isolated adipocytes (106 cells) in 2 ml of KRBH- buffer for 4 h at
37uC with 5% CO2 in the absence and in the presence of 1 mM
isoproterenol. After 4 h of incubation 1ml of the incubation
medium was removed and acidified with 100 ml of 30%
trichloroacetic acid. The mixture was vigorously shaken and then
centrifuged at 3000g for 10 min at 4uC. A volume of 700 ml of
surnatant was collected and neutralized with 80 ml of 10% KO
and assayed for glycerol content (GPO Trinder, SIGMA)
Protein preparation
Adipose tissue was homogenized in a lysis buffer containing
20 mM Tris (pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton
X-100, 10 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride.
The homogenate was then centrifuged at 3000 rpm for 30 min at
4uC. The top and bottom layers were discarded, and the
intermediate phase was collected and assayed for the protein
concentration by using the the Bradford Reagent (Bio-Rad).
Immunoblotting
Proteins were separated on 12% SDS-PAGE and transferred onto
a nitrocellulose filter by electroblotting. Filters were saturated with
a solution of 5% dry milk in Tris-buffered saline (TBS) and
incubated with a polyclonal primary antibody anti-mouse
uncoupling protein-1 (UCP-1) raised in rabbit (Calbiochem, cat.
no 662045), at a 1:2000 dilution in TBS 0.1% Tween with 2% dry
milk. After three washes with TBS, the filter was incubated for 1 h
in the anti-rabbit secondary antibody (horseradish peroxidase
conjugated), diluted 1:3000 in TBS 0.1% Tween 2% dry milk.
Specific protein expression was visualized using a chemilumines-
cent assay (Amersham Pharmacia/Biotech, Piscataway, NJ), after
exposure to x-ray film for 1–5 min. b-tubulin (TO198, Sigma, St.
Louis MI), at a dilution of 1:600, was used as an internal control to
verify equal loading of the protein. The intensity of the bands was
quantified using Quantity One 1-D Analysis software (Biorad,
Hercules CA).
Isolation of mitochondria and CPT assay
Adipose tissue mitochondria were isolated by differential centri-
fugation. Freshly isolated tissue was minced on ice and then
homogenized with a Potter-Elvehjem in homogenization buffer 1
(220 mM mannitol, 70 mM sucrose, 20 mM Tris-Hcl, 1 mM
EDTA) 1:6 (w/v). The homogenate was centrifuged at 22.500 g
for 25 min at 4uC and, after removing of the fat layer, the pellet
was resuspended in the same buffer. This suspension was
centrifuged at 700 g for 10 min at 4uC. Pellet was discarded and
supernatant was then recentrifuged at 15000 g for 30 min at 4uC
to pellet mitochondria. Mitochondria were immediately used for
CPT assay or stored at – 80uC.
Carnitine palmitoyl transferase activity was assayed spectro-
photometrically following carnitine-dependent CoA liberation in
presence of palmitoyl-CoA and DTNB at 412 nM, according to
the method of Bieber et al. [41] with some modifications. The
reaction buffer was: 116 mM Tris-HCl, 0.09% Triton, 1.1 mM
EDTA, 35 mM palmitoyl-CoA, 0.12 mM DTNB and 3.3 mM
carnitine in a final volume of 0.9 mL. Assay buffer without
mitochondria was used as a blank. Mitochondrial proteins
(100 mg) were then brought to a final concentration of 1 mg/mL
in buffer 1 containing 0.1% Triton, added to the assay buffer,
incubated 30 s and then the reaction was started. Change in
absorbance was monitored for 3 min and CPT activity was
expressed as nmol CoA/min x mg protein.
MRI
Magnetic resonance images (MRI) were acquired using a Biospec
Tomograph (Bruker, Germany) operating at 4.7 T. Mice were
anaesthetized through Avertin (10 ml/gram of body weight) and
placed in the supine position in a 7.2 i.d. bird cage volume coil.
This large coil was chosen in order to achieve a uniform excitation
of the whole mice body. Transversal spin echo images were
acquired using the following parameters: TR=530 ms;
TE=10.2 ms; Slice thickness = 2 mm; FOV=663 cm2, Matrix
size = 2566128 (in plane space resolution = 2346234 m2 ). Three
packages of 15 contiguous slices were acquired in order to cover
the whole mice body. MRI data were analyzed using the software
Paravision (Bruker, Germany). A single investigator, blinded to the
experimental groups of mice, analyzed the images. Fat tissue
appears strongly hyperintense compared to the remaining body
organs. Pixels attributable to fat could be segmented in each slices
by a simple threshold algorithm: pixels having signal intensity
higher then the threshold value were attributed to fat tissue. After
thresholding each slice was visually inspected in order to verify that
the algorithm correctly selected only fat pixels. A similar algorithm
based on a threshold value was used for the quantification of total
body volume. In each slice the total fat and body volumes were
calculated according to:
Fat (or body) volume~N  pixel area  slice thickness:
Where N represents the number of pixels attributed to fat or to
body, respectively.
Body Fat Analysis by DEXA
Dual Energy X-ray Absorption (DEXA, PIXImus, Lunar Corp)
was used to evaluate percent body fat content in mice from sv129/
C57Bl6. Animals were anesthetized with mixture of ketamine and
xylazine, placed on the scanning apparatus, and bone mineral
density (BMD) and percent body fat determined. Animals were
kept in a warm environment under a heating lamp until fully
recovered.
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Assessment of liver triglyceride (TG) content
Liver triglyceride content was determined by extracting total lipids
from liver samples with chloroform:methanol (2:1 vol/vol) as
described by Folch et al. [42], separating the chloroform and
methanol–water phases twice, discarding the upper phase and
finally evaporating the lower phase under N2. For the assay,
samples were resuspended in 100 ml chloroform; 30 ml were
quickly transferred to glass tubes in duplicate and air dried. After
addition of 50 ml of bidistilled water they were vortexed and
incubated at 37uC in a shaking water bath for 10 min. One
milliliter of GPO Trinder reagent (Sigma-Aldrich) was added to
the tubes, which were then gently mixed and incubated at 37uC
for 5 min. The absorbance of duplicate samples was read at
540 nm in a spectrophotometer. The range of linearity of this
method based on GPO Trinder reagent is up to 1000 mg/dl and
the detection limit is 1.0 mg/dl.
Histological analysis
Animals were anesthesized with Avertin and then perfused using
4% paraformaldehyde. Epidydimal adipose tissue samples were
then post-fixed using 4% paraformaldehyde for 12-24 h and
embedded in paraffin. Five micrometers sections were mounted on
charged glass slides and then stained with hematoxilin-eosin.
MEF isolation and treatments
Primary MEFs were isolated from 12 days post-coitum mouse
embryos [43]. Embryos were surgically removed, and separated
from maternal tissue and the yolk sack. The bodies were minced
finely and then incubated in a solution of trypsin:EDTA (0.05%
trypsin; Sigma; 1 mM EDTA, glucose, 1x PBS) with shaking at
37uC for 15–30 min. The solution was allowed to settle for 2 min,
and the surnatant was centrifuged for 3 min at 1200 rpm. The
resulting pellet was resuspended in culture medium and cells were
plated at 104 cells/cm2 . Attached cells then constituted passage 1.
All primary MEFs were maintained in Dulbecco’s Modified
Eagle Medium (DMEM, Gibco) supplemented with 10% fetal
bovine serum (FBS, Gibco), 100 units of penicillin and 100 mg/ml
streptomycin. Cultured cells were maintained at 37uC in
a humidified 5% CO2 atmosphere. For adipocyte differentiation
MEFs were plated on 35 mm dishes and at two days post-
confluence the medium was supplemented with 5 mM dexameth-
asone (Sigma), 0.2 mM isobutylmethylxanthine (Sigma) 1 mM
BRL-49653 (kindly provided by Glaxo Smithkline) and 10 mg/ml
insulin(Sigma) for 3 days followed by supplementation with only
insulin and BRL-49653 from day 3.
Statistical analysis
The number of mice in each experimental group is indicated in
the figure legends. All values are expressed as means6SEM.
Pairwise comparisons of quantitative phenotypes between mice of
different genotypes (e.g. obese ctsk2/2 versus obese ctsk +/+)
were assessed by 2-tailed Student’s t-test. When more than 2
groups were analyzed, 2-way ANOVA followed by Bonferroni
post-test for selected comparisons (e.g young ctsk +/+ versus young
ctsk2/2) was used. Spearman linear regression analysis was
performed to evaluate association between variables. A signifi-
cance limit of P,0.05 was set.
SUPPORTING INFORMATION
Figure S1 A. Representative immunoblotting showing UCP-1
and b-tubulin protein expression in mouse BAT of C57Bl6 ctsk +/
+ and C57Bl6 ctsk 2/2 mice. Total protein extracts from mouse
BAT(10ug) were separated by SDS-PAGE and transferred onto
nitrocellulose. Blots were respectively probed with primary
antibodies against mouse UCP-1 and b-tubulin and horseradish
peroxidase-conjugated secondary antibody. B. Bar graph showing
the relative expression of UCP-1 in the BAT of HFD ctsk2/2
and +/+ mice. Quantity One 1-D Analysis software was employed
to quantify band intensity. Levels of UCP-1 were corrected for by
the intensity of the corresponding b-tubulin band.
Found at: doi:10.1371/journal.pone.0000683.s001 (3.97 MB TIF)
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